User:Mr. Ibrahem/Empagliflozin

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Empagliflozin
Clinical data
Trade namesJardiance, others
Other namesBI-10773
AHFS/Drugs.comMonograph
MedlinePlusa614043
License data
Pregnancy
category
Routes of
administration		By mouth
Drug classSodium-glucose cotransporter-2 (SGLT2) inhibitor[2]
Legal status
Legal status
Identifiers
  • (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
Chemical and physical data
FormulaC23H27ClO7
Molar mass450.91 g·mol−1
3D model (JSmol)
  • C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl
  • InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
  • Key:OBWASQILIWPZMG-QZMOQZSNSA-N

Empagliflozin, sold under the brand name Jardiance among others, is a medication used together with diet and exercise to treat type 2 diabetes.[2][6] It is less preferred than metformin and sulfonylureas.[7] It may be used together with other medications such as metformin or insulin.[2][6] It is not recommended for type 1 diabetes.[2] It is taken by mouth.[2]

Common side effects include urinary tract infections, fungal infections of the groin, and joint pains.[2] Rarer but more serious side effects include a skin infection of the groin called Fournier's gangrene and a form of diabetic ketoacidosis with normal blood sugar levels.[2][8] Use in pregnancy and breastfeeding is not recommended.[7] Use is not recommended in those with significant kidney disease, though it may help slow the progression of mild kidney problems.[2][6] Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and works by increasing sugar lost in the urine.[2]

Empagliflozin was approved for medical use in the US and in the European Union in 2014.[2][9][10][11] It is on the World Health Organization's List of Essential Medicines.[12] A month supply in the UK costs the NHS about £36.59 as of 2019.[7] In the US, the wholesale cost of this amount is about US$442.[13] In 2017, it was the 228th most commonly prescribed medication in the United States, with more than two million prescriptions.[14][15]

References[edit]

  1. ^ a b "Empagliflozin (Jardiance) Use During Pregnancy". Drugs.com. 30 August 2018. Archived from the original on 5 August 2019. Retrieved 10 February 2020.
  2. ^ a b c d e f g h i j "Empagliflozin Monograph for Professionals". Drugs.com. AHFS. Archived from the original on 6 April 2019. Retrieved 21 December 2018.
  3. ^ "Jardiance 10 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 20 September 2020. Retrieved 10 February 2020.
  4. ^ "Jardiance 25 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 23 October 2019. Archived from the original on 22 September 2020. Retrieved 10 February 2020.
  5. ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 17 May 2021. Retrieved 8 September 2020.
  6. ^ a b c Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB (December 2018). "Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)". Diabetologia. 61 (12): 2461–2498. doi:10.1007/s00125-018-4729-5. PMID 30288571.
  7. ^ a b c British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 691. ISBN 9780857113382.
  8. ^ "FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes". U.S. Food and Drug Administration (FDA). 9 February 2019. Archived from the original on 13 December 2019. Retrieved 18 March 2019.
  9. ^ "Drug Approval Package: Jardiance (empagliflozin) Tablets NDA #204629". U.S. Food and Drug Administration (FDA). 8 September 2014. Archived from the original on 11 February 2020. Retrieved 10 February 2020.
  10. ^ "Jardiance: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 11 February 2020. Retrieved 10 February 2020.
  11. ^ "Jardiance EPAR". European Medicines Agency (EMA). Archived from the original on 28 August 2021. Retrieved 10 February 2020.
  12. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  13. ^ "NADAC". Centers for Medicare and Medicaid Services. 27 February 2019. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
  14. ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
  15. ^ "Empagliflozin - Drug Usage Statistics". ClinCalc. Archived from the original on 13 April 2020. Retrieved 11 April 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Empagliflozin&oldid=1208076486"